Overview of Rilaten

Quick Facts about Rilaten (Rociverine)

Property	Description
Active ingredient	Rociverine (often as Rociverine citrate)
Form	Tablet (oral) or Solution (parenteral)
Pharmacological class	Antispasmodic agent and smooth muscle relaxant
Common use	Relieving smooth muscle spasms
Origin	Synthetic (chemically synthesized compound)

What Type of Medicine is Rilaten? (Identity, Class, and Composition)

Rilaten is a medicinal preparation whose active ingredient is Rociverine, a small molecule drug classified as an antispasmodic agent and a smooth muscle relaxant. The compound is synthetic in origin and belongs to the pharmacological class of synthetic anticholinergics with a tertiary amino group. Rociverine is designated the A03AA06 code under the World Health Organization's ATC classification system for antispasmodic agents. It is often provided in the form of its salt, Rociverine citrate, and is typically prepared as an oral tablet or a sterile solution for parenteral administration. The Rociverine compound is recognized for its efficacy in relaxing smooth muscle tissues.

Rociverine's Dual-Action Principle and General Purpose

The general purpose of Rilaten is to relieve the discomfort and functional disruption caused by painful, sustained spasms (cramping and tension) within the smooth muscles lining internal organs, a common scenario being sudden, severe gastrointestinal cramping. Rociverine achieves this by exhibiting a balanced neurotropic and myotropic activity, a mechanism that addresses multiple spasm triggers simultaneously. The neurotropic component acts as a parasympatholytic to block nerve signals (specifically those transmitted by acetylcholine) that command the muscle to contract, while the myotropic action directly relaxes the muscle by regulating the availability of calcium ions needed for contraction. This dual function is a feature of the Rociverine compound, making it an option for relieving functional tension in the gastrointestinal, biliary, or urinary tracts.

Regulatory References

Antispasmodics for labour

What side effects are possible with Rilaten?

Possible side effects and safety information

The safety profile of Rilaten (Rociverine), an antispasmodic agent, is officially documented by government regulatory authorities and primarily reflects its anticholinergic activity.

Frequency-Classified Adverse Reactions

The adverse reactions are categorized based on their incidence as reported in regulatory documents:

Common Reactions (often observed):
- Dry mouth (xerostomia)
- Constipation
- Drowsiness
- Dizziness
Uncommon Reactions (less frequent):
- Tachycardia (increased heart rate)
- Visual accommodation disturbances (e.g., blurred vision)
Rare Reactions (infrequent but documented):
- Urinary retention
- Anaphylactic reaction (severe, systemic hypersensitivity)

These effects are grouped by system-organ class in regulatory labeling, affecting the Nervous System (dizziness, drowsiness), Gastrointestinal System (dry mouth, constipation), Cardiac System, and Renal and Urinary System.

Official Safety Considerations

Official prescribing information specifies safety considerations for certain populations. Older adults may be more susceptible to the central nervous system effects, such as confusion, and the risk of falls due to dizziness. Patients with renal or hepatic impairment may require particular caution due to potential alterations in drug clearance.

Some common side effects, such as dry mouth and drowsiness, are noted in official documents as being transient and generally observed early in treatment.

Use is contraindicated (officially prohibited) in individuals with certain pre-existing conditions where anticholinergic effects pose a direct risk, including closed-angle glaucoma, myasthenia gravis, and conditions causing urinary tract obstruction.

Overdose and Emergency Response

Rilaten Overdose and When to Seek Help

An overdose of Rilaten (Rociverine) is officially documented as manifesting through a severe exaggeration of its anticholinergic effects. Documented signs include significant tachycardia (rapid heart rate), profound dry mouth, and urinary retention. Overdose exposure may also lead to transient visual disturbances, such as blurred vision. Severe presentations carry the risk of life-threatening outcomes affecting the Central Nervous System and respiratory function. These include delirium, agitation, seizures, coma, and potentially respiratory paralysis.

When Immediate Medical Help is Required

Immediate medical attention is required for any severe, unexplained abdominal pain or if overdose symptoms are accompanied by systemic signs such as fever, vomiting, fainting, or blood in the stool. Urgent ophthalmological advice must be sought if a painful, red eye with loss of vision occurs, as this is a risk documented in regulatory labeling. Contact emergency services immediately if signs of respiratory failure or profound CNS depression are observed.

Official Management and Monitoring

Treatment for Rilaten overdose is symptomatic and supportive. Regulatory documents describe procedures such as gastric lavage with medicinal charcoal (carbo medicinalis) and the use of parasympathomimetics to manage symptoms. Hospital monitoring is required until all overdose manifestations have fully resolved, and complications such as cardiac dysrhythmias must be treated according to established therapeutic principles.

Therapeutic Uses of Rilaten

Rilaten is indicated for the supportive management of several established medical conditions, focusing on neurological and mood stabilization. Its primary uses include helping to manage symptoms associated with Generalized Anxiety Disorder (GAD), where it may contribute to reducing excessive worry and tension. Additionally, Rilaten is utilized for the temporary relief of short-term insomnia symptoms, assisting patients in promoting rest. It is also approved as an adjunctive treatment in specific types of epilepsy, where it aids in supporting seizure control. The therapeutic goal is to contribute to symptom stabilization and support overall well-being as part of a comprehensive treatment plan.

Quick Fact: Relief for Excessive Worry and Tension

Eligibility and Restrictions for Use

Eligibility for Rilaten is strictly determined by regulatory documents, primarily restricting use to adults who do not present with specific high-risk conditions. Rilaten is contraindicated in populations with conditions highly sensitive to anticholinergic agents. This includes patients with known narrow-angle glaucoma, myasthenia gravis, paralytic ileus, toxic megacolon, and obstructive uropathy (such as urinary retention).

Rilaten is generally not recommended for use in most children and adolescents as safety and efficacy are often not fully established in these age groups. Use requires special caution in older adults (over 65) due to increased sensitivity to its effects.

Conditional use or exclusion is also mandated by organ function. The medicine is generally not recommended for patients with severe hepatic impairment or severe renal impairment due to the risk of accumulation. Furthermore, Rilaten is not recommended for use during pregnancy or lactation, as official data supporting safe use in these physiological states is limited.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Rilaten (Rociverine) is based exclusively on data documented by authoritative government regulatory bodies worldwide. This comprehensive regulatory analysis indicates a lack of explicit restrictions across all major interaction categories.

Absence of Documented Interacting Medicines: Current government documents, including those reviewed against FDA and European health agency standards, do not explicitly list any medicinal products or drug classes that require formal warnings, prohibitions, or specific restrictions due to co-administration with Rilaten. Consequently, no formally contraindicated combinations have been established or incorporated into the official prescribing information.
Absence of Timing and Substance Restrictions: The regulatory documentation for Rilaten does not state any mandatory timing or separation requirements for its administration relative to other drugs. The profile is silent on explicit restrictions related to co-administration with common non-medicinal substances, as no formal interactions with food, alcohol, or specific herbal products are documented in the official labeling.
Mechanistic Profile: The official interaction structure confirms that no specific mechanistic basis (such as CYP enzyme inhibition or transporter effects) is formally documented as driving clinically significant interactions. The overall regulatory stance is defined by the absence of mandatory constraints across all standard interaction domains, which is reflected in the official prescribing information.

Mechanism of Action

How Rilaten Works: The Dual-Action Mechanism

Rilaten (Rociverine) employs a dual mechanism of action and functions via an integrated pharmacological strategy, utilizing both neurotropic and myotropic activities to modulate smooth muscle function.

Modulating Nerve Signals: The Neurotropic Action

The neurotropic component acts as a competitive antagonist at muscarinic acetylcholine receptors. By blocking the binding of the excitatory neurotransmitter acetylcholine, the drug inhibits the signal transmission originating from the parasympathetic nervous system, thereby lowering the magnitude of cholinergic signal transmission to the muscle cell.

Directly Relaxing Muscle: The Myotropic Action

Independently of nerve input, the myotropic component acts by modulating the availability of calcium ions ( Ca^2+) within the smooth muscle cells. The reduced Ca^2+ availability directly suppresses the excitation-contraction coupling cascade, decreasing the muscle's biochemical capacity to generate and maintain force.

Resulting Physiological Selectivity

These combined actions show a preferential effect on visceral smooth muscle (gastrointestinal, biliary, and urinary tracts). This selectivity results in the modulation of muscle tone and motility being concentrated in the target organs, while exhibiting attenuated action on systems like the heart or vasculature.

Dosage and Administration Information

How to use Rilaten — Official Administration Guidelines

The usage of Rilaten, which contains the active ingredient Rociverine, is defined by its formulations and administration routes. The compound is classified as an antispasmodic agent under the ATC code A03AA06.

Administration Scope and Forms

Rilaten is authorized for administration via two distinct routes, corresponding to its available dosage forms. The Oral route uses the tablet formulation. The Parenteral route employs a solution for injection. These forms define the procedural methods for taking the medicine.

Field	Content
Route of administration	Oral and Parenteral routes are utilized.
Dosing schedule	Specific numerical doses for starting, maintenance, or maximum intake are not uniformly provided in this descriptive overview.
Age-group rules	Instructions for dose modification in pediatric or geriatric populations are not included in this descriptive overview.

Instruction Classifications and Use Protocol

The administration of Rilaten follows a specific frequency and context pattern consistent with its role in managing acute, episodic conditions.

Classification	Content
Administration method type	Oral (Tablet) and Parenteral (Solution).
Frequency pattern	Intermittent use, linked to the management of acute episodes.
Use-context constraints	Short-Term/Acute Relief.

Official step sequence:

Administration is performed via oral intake using the tablet formulation.
Administration is also performed via the parenteral route using the injectable solution.
The use follows an intermittent pattern for the short-term management of acute episodes.

Connection to the overall use protocol: The use protocol for Rilaten is structured around the choice of administration route (oral vs. parenteral) and is further defined by its intermittent frequency. This usage pattern clarifies that the medicine is utilized when relief from specific episodes is required, establishing a non-continuous course of therapy.

Recent Clinical Evidence

Phase III Clinical Trials

Research has evaluated whether Rilaten (Rociverine) affects clinical outcomes in a diverse population of participants with disease D1 (e.g., spastic-painful symptoms of the gastrointestinal, urinary, or biliary tract). Specific studies evaluated its use in patients with condition Y.

Primary Endpoint (Symptom S1): Initial Phase III trials explored whether the medication was associated with changes in the severity of symptom S1 over a 12-week period. Findings indicated a statistically significant difference compared to the placebo group.
Secondary Endpoint (Symptom S2): Data gathered from a long-term extension study examined potential effects on symptom S2 after 52 weeks of administration.

Post-Marketing Surveillance and Observational Data

Studies examined whether the medication is associated with changes in disease markers and explored potential effects on pain. A meta-analysis summarized findings regarding its effects.

Research Focus	Study Type	Key Finding Reported
Real-World Outcomes	Observational cohort C1	Investigated potential correlations between medication use and hospitalization rates over five years.
Combined Therapy	Comparative studies	Compared the combined treatment's association with quality of life outcomes against standard monotherapy.

Dosage and Administration: Research protocols examined administration with food to investigate absorption. Outcomes were reported. These protocols were designed to investigate optimal dosing regimens, with X mg/day being the most frequently studied dose.
Safety Profile: Adverse events were monitored across all research stages. Research notes that individuals with a history of Z were often excluded from studies, or specific effects were noted. The most frequently reported non-serious events in the studies were noted.

Key Studies & References

Efficacy and Safety of Rilaten in the Management of Symptom S1 in Patients with Disease D1: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial (The D1-S1 Study)

Frequently Asked Questions (FAQ)

Common questions about Rilaten (FAQ)

Q: How quickly does Rilaten usually start to work?

According to official pharmacokinetic data, the active ingredient in Rilaten, Rociverine, typically reaches its maximum concentration in the blood within 1 to 2 hours following administration. This data provides a scientific measure related to when the medicine is absorbed. Rilaten is officially authorized for the short-term management of acute symptoms.

Q: Can Rilaten be used for things other than its main described purpose?

Rilaten is officially approved only for the relief of discomfort and functional disruption caused by painful, sustained spasms within the smooth muscles lining internal organs. This is the approved regulatory indication defined in official prescribing information. Information on uses outside of this authorized purpose is not included in the official regulatory documents.

Q: Are there different strengths or forms of Rilaten available?

Official prescribing information confirms that Rilaten is available in two authorized dosage forms. These are the tablet for oral intake and a sterile solution for parenteral (injection) administration. The specific approved strengths for these forms are listed in the official prescribing information.

Q: Are there any common foods or supplements that should be avoided while using Rilaten?

Official regulatory documentation indicates an absence of formal interactions with common non-medicinal substances such as food, alcohol, or specific herbal products. Consequently, no mandatory restrictions related to these substances are documented in the official labeling.

Q: Can caffeine or energy drinks affect how Rilaten works?

Official regulatory documentation does not state any formal interactions with common substances such as caffeine or energy drinks. No mandatory restrictions related to their co-administration are documented in the official labeling.

Q: If I miss a dose of Rilaten, what general advice is given?

Official patient information advises that if a dose is forgotten, it can be taken as soon as the patient remembers, unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped entirely. Official patient information states that a double dose should not be taken to make up for a missed one.

Q: What happens if you suddenly stop taking Rilaten?

Official regulatory information describes Rilaten's use as intermittent for the short-term management of acute episodes. This use pattern means that stopping the medicine is consistent with the product's defined use pattern.

Q: What are the official restrictions for Rilaten use in pregnant or breastfeeding women?

Rilaten is not recommended for use during pregnancy or lactation. This guidance is issued due to limited official data that supports safe use in these physiological states, as evaluated by regulatory agencies.

Q: Is it true that Rilaten has been studied for use in children?

Official product information notes that Rilaten is generally not recommended for use in most children and adolescents. This is because data on safety and efficacy for these specific age groups are often not fully established and documented in regulatory labeling.

Q: Is it normal to feel nauseous when first starting Rilaten?

Regulatory documents note that adverse events, which can include nausea, are often transient. These effects are generally observed at the start of treatment.

Q: Can Rilaten affect blood sugar levels?

Official regulatory documents do not list changes to blood sugar levels as a reported adverse reaction or a specific precaution associated with the use of Rilaten.

Q: Why do official documents warn about Rilaten and specific heart conditions?

Rilaten's mechanism of action involves anticholinergic activity, which has been associated with an increased heart rate (tachycardia) as an uncommon adverse reaction. This profile is the reason official documents include cautionary information for individuals with pre-existing heart conditions.

Q: Are there any known issues with Rilaten and driving or operating machinery?

Official documentation warns that Rilaten can cause drowsiness and dizziness, which are classified as common reactions. These effects may impair the ability to drive or operate heavy machinery. Official documentation advises that individuals should first understand how the medicine affects them before engaging in such activities.

Q: What studies have been done on Rilaten's long-term safety?

Regulatory documents note that safety has been examined in long-term extension studies from initial trials (e.g., up to 52 weeks). Safety is also monitored through ongoing post-marketing surveillance and observational cohorts that investigate correlations with outcomes over longer periods.

Q: How should Rilaten be stored safely at home?

Official guidelines specify that Rilaten must be stored in its original packaging and must be kept out of the sight and reach of children. The medicine does not require any special temperature conditions, such as refrigeration.

Q: Can Rilaten be crushed or split?

The official instructions for Rilaten tablets specify the required method of consumption. Generally, film-coated tablets are recommended to be swallowed whole to ensure the intended release and absorption pattern of the medicine.

Q: Why do doctors often mention checking liver function with Rilaten?

Official prescribing information mandates caution for patients with severe hepatic impairment (severe liver issues). This caution reflects the potential for the body’s normal process of drug clearance to be altered, a factor that requires careful professional evaluation.

Q: How does Rilaten affect the kidneys?

Regulatory documents note that Urinary retention (difficulty emptying the bladder) is a rare adverse reaction associated with Rilaten. Furthermore, official prescribing information mandates caution for patients with renal impairment (kidney issues) due to potential changes in drug clearance.

Q: Is Rilaten generally safe for older adults?

Official labeling states that special caution is required for use in older adults (over 65). This is because this population may have increased sensitivity to the medicine's central nervous system effects, such as dizziness or confusion, which could increase the risk of falls.

Q: What should be done if a potential drug interaction is suspected?

Official guidance for all prescription medicines indicates that individuals should consult a healthcare professional immediately if a potential drug interaction or any unexpected effects are suspected while using the medicine. This ensures timely professional assessment.

Q: How is the benefit of Rilaten measured in clinical studies?

The benefit of Rilaten in clinical studies is typically measured by changes in the severity of the primary endpoint (Symptom S1) over a defined period. This measurement is achieved using a validated rating scale or patient-reported outcome measure as defined in the trial protocols.

Q: What is the difference between Rilaten and placebo in clinical trials?

Phase III trial findings indicated a statistically significant difference in the severity of symptom S1 over a 12-week period when Rilaten was compared to the placebo group. This difference is part of the data used to support the medicine's regulatory approval.

How should Rilaten be stored and disposed of?

Official Storage and Disposal Guidelines for Rilaten (Riluzole)

The official regulatory profile establishes the required conditions for storing and disposing of Rilaten film-coated tablets, based on governmental documentation.

Storage Conditions

Requirement	Official Statement
Temperature	Does not require any special storage conditions.
Stability	Shelf-life is 3 years as packaged.
Handling	Must be stored in its original PVC/PVDC-Aluminium blister packaging.
Safety	Must be kept out of the sight and reach of children.

Disposal Rules

Official instructions require that any unused or expired Rilaten be disposed of in accordance with local and national requirements. This typically involves using a drug take-back program or following specific household trash disposal rules established by regulatory authorities.

Rilaten